EpiCast Report: Cystic Fibrosis - Epidemiology Forecast to 2025

EpiCast Report: Cystic Fibrosis - Epidemiology Forecast to 2025

  • April 2017 •
  • 73 pages •
  • Report ID: 4883760 •
  • Format: PDF
EpiCast Report: Cystic Fibrosis - Epidemiology Forecast to 2025

Summary
Cystic Fibrosis (CF) is an inherited disorder that affects the cells that produce mucus, sweat and digestive juices, and also causes severe damage to the lungs, digestive system and other organs. These secreted fluids are normally thin and slippery. But in people with CF, a defective gene, known as the CFTR gene, causes the secretions to become sticky and thick. Instead of acting as a lubricant, the secretions plug up tubes, ducts and passageways (Mayo Clinic, 2016). In the lungs, the mucus clogs the airways and traps bacteria leading to infections, extensive lung damage and eventually, respiratory failure.

Key differences in the CF epidemiology between countries are influenced by genotype mutations, national screenings, and surveillance systems through national registries. The UK has the greatest prevalence proportion of CF, which may be the result of a strong presence of the mutations in the country (UK CFR, 2014). Reports indicate that British and French ancestries are the origins of CF-causing mutations (Physicians Committee for Responsible Medicine, 2008). National CF screenings are also imperative in detecting and capturing the true CF prevalence of a country.

According to the forecast adjusted for underestimation of registry data, the diagnosed incident cases of CF in the 7MM will decrease from 2,217 cases in 2015 to 2,074 cases in 2025, at an AGR of negative 0.64%. The US will have the highest number of diagnosed incident cases of CF among the 7MM throughout the forecast period, while Germany will have the lowest.

In the 7MM, based on registry data, our epidemiologists forecast that the diagnosed prevalent cases of CF will increase from 63,571 cases in 2015 to 73,368 cases in 2025, at an AGR of 1.54%. The US will have the highest number of diagnosed prevalent cases of CF among the 7MM throughout the forecast period, while Spain will have the lowest.

The report "EpiCast Report: Cystic Fibrosis - Epidemiology Forecast to 2025" provides an overview of the risk factors, comorbidities, and the global and historical trends for CF in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Canada). It includes a 10-year epidemiological forecast for the diagnosed incident cases of CF, diagnosed prevalent cases of CF, and CF mortality based on county-specific registry data. Moreover this report provides the in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Scope
- The Cystic Fibrosis (CF) EpiCast Report provides an overview of the risk factors and global trends of CF in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Canada). It includes a 10-year epidemiology forecast of diagnosed incident cases of CF, diagnosed prevalent cases of CF, and CF mortality segmented by sex in these seven markets. Diagnosed prevalent cases of CF are further segmented by age (starting from zero years of age and up to 85 years and older), specific mutation type, and chronic Methicillin-resistant Staphylococcus aureus (MRSA) infection.
- The CF epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy
The CF EpiCast series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global CF market.
- Quantify patient populations in the global CF market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CF therapeutics in each of the markets covered.
- Identify the percentage of CF diagnosed prevalent cases by age, sex, specific mutation type, and MRSA infection.
Loading...

We are very sorry, but an error occurred.
Please contact [email protected] if the problem remains.